Although the kidney showed deterioration following HSCT, the functional improvements and benefits seen in other symptoms that are hallmarks for ACDase deficiencies, along with a significantly increased survival rate, makes HSCT an interesting treatment option for those with FD or SMA-PME. The gene discussed is CSTB; the disease is Fabry disease.